Boxin Bio

Hangzhou Baicreat Pharma-Tech (also known as Baixin Biopharmaceutical or Boxin Bio) is an innovative Chinese biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the discovery and development of novel therapeutics for inflammation, autoimmune diseases, and oncology, leveraging its proprietary PROTAC (Proteolysis-Targeting Chimera) technology platform. Its lead candidate, BCR-0008, is a first-in-class oral STAT6 degrader that received IND approval from China's NMPA in September 2026 for the treatment of Th2-mediated inflammatory diseases such as atopic dermatitis and asthma. Baicreat's pipeline also includes preclinical and discovery-stage programs targeting VAV1, NLRP3, PAD4, and POLQ, utilizing both targeted protein degradation and small-molecule inhibition strategies.